Last reviewed · How we verify
Levofloxacin quadruple regimen
At a glance
| Generic name | Levofloxacin quadruple regimen |
|---|---|
| Sponsor | Ayman Magd Eldin Mohammad Sadek |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment (PHASE3)
- Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin (PHASE4)
- Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection (NA)
- Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies (PHASE3)
- Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levofloxacin quadruple regimen CI brief — competitive landscape report
- Levofloxacin quadruple regimen updates RSS · CI watch RSS
- Ayman Magd Eldin Mohammad Sadek portfolio CI